Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (1): 127-131.

• Other Liver Diseases • Previous Articles     Next Articles

Clinical efficacy of apatinib combined with GEMOX in patients with gallbladder cancer and its influence on tumor markers

JIANG Li-li1, ZHOU Su-kang2, JU Ye3   

  1. 1. Department of Pharmacy, Haimen District People′s Hospital, Nantong 226100,China;
    2. Department of Equipment,Haimen District People′s Hospital,Haimen District People′s Hospital, Nantong 226100,China;
    3. Department of Oncology,Haimen District People′s Hospital,Haimen District People′s Hospital, Nantong 226100, China
  • Received:2024-10-16 Online:2026-01-31 Published:2026-03-30
  • Contact: JU Ye, Email: judy5534@163.com

PDF (PC)

1

Abstract: Objective To evaluate the efficacy of Apatinib combined with GEMOX in the treatment of gallbladder cancer (GC). Methods 98 GC patients admitted to our hospital from January 2020 to June 2023 were enrolled and divided into 2 groups by envelope method, 48 cases in the control group were treated with GEMOX, 50 cases in the observation group were treated with apatinib, and the efficacy of the two groups was compared. Results The overall response rate (ORR) and disease control rate in the observation group were 78.00% (39/50) and 86.00% (43/50), which were higher than those in control group (58.33% (28/48) and 68.75% (33/48) (P<0.05). After 8 weeks of treatment, the CEA (15.69±2.74) ng/mL, VEGF (259.64±40.87) ng/mL and soluble interleukin-2 (sIL-2R) (536.29±42.05) U/mL in the observation group were lower than those in the control group (22.17±3.06) ng/mL, (324.52±49.82) ng/mL, (638.95±52.47) U/mL (P<0.05). After 8 weeks of treatment, CD4+ (30.14±4.02) % and CD4+/CD8+ (0.79±0.12) in observation group were lower than those in control group (35.21±4.26) % and (0.93±0.14). CD8+ (41.26±4.29) % was higher than that in the control group (38.56±5.02) % (P<0.05). The KPS score (84.26±5.41) in the observation group was higher than that in the control group (80.66±5.86), and the BFI score (2.96±0.47) was lower than that in the control group (4.29±0.63) (P<0.05). The incidence of elevated blood pressure, proteinuria, and hand foot syndrome (4.00%, 6.00%, 4.00%) in the observation group was lower than that in the control group (6.25%, 6.25%, 4.17%), and the incidence of nausea and vomiting (8.00%) was higher than that in the control group (4.17%, P>0.05). Two groups of patients were followed up for 6 months, 2 cases fell off due to the loss of contact information, 49 cases in the observation group and 47 cases in the control group completed the final follow-up. The survival rate of the observation group was 91.84% (45/49), which was higher than that of the control group (82.98% (39/47), which was statistically analyzed by Log-rank χ2 test (χ2=1.721, P=0.190). Conclusion Apatinib combined with GEMOX has significant therapeutic effect on GC patients, which can effectively improve the immune function of patients, enhance the quality of life of patients, reduce the fatigue of patients, improve tumor markers, and the clinical safety is reasonable.

Key words: Apatinib, GEMOX scheme, Gallbladder cancer, Tumor marker